



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/030,441	05/16/2002	Hung Y. Fan	UC11150-1	6562

7590 08/26/2003
LISA A. HAJLE, PH.D.
GRAY CARY WARE & FREIDENRICH LLP
4365 EXECUTIVE DRIVE
SUITE 1100
SAN DIEGO, CA 92121

EXAMINER	
CHEN BROWN, STACY	
ART UNIT	PAPER NUMBER
1648	

DATE MAILED: 08/26/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application N .	Applicant(s)
	10/030,441	FAN ET AL.
	Examiner Stacy B Chen	Art Unit 1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 16 May 2002.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

4) Claim(s) 1-59 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-59 are subject to restriction and/or election requirement.

Disposition of Claims

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claims 1-12 and 37-41, drawn to a Jaagsiekte retrovirus.
- Group II, claims 13-21 and 55-58, drawn to a genome and vector encoding a Jaagsiekte retrovirus.
- Group III, claims 22-24, drawn to a method for producing a Jaagsiekte retrovirus using a Jaagsiekte retrovirus genome vector.
- Group IV, claims 25-36, drawn to a method for treating a subject by administering a Jaagsiekte retrovirus vector genome.
- Group V, claim 42, drawn to a method for inducing an immune response using a Jaagsiekte retrovirus.
- Group VI, claims 43-44, drawn to an antibody that binds Jaagsiekte retrovirus.
- Group VII, claims 45-49, drawn to a method of inhibiting Jaagsiekte retrovirus binding using the antibody that binds to Jaagsiekte retrovirus.
- Group VIII, claims 50-53, drawn to a method of identifying a compound that binds to a Jaagsiekte retrovirus.

- Group IX, claim 54, drawn to a method of inhibiting expression of a retrovirus in a cell with antisense oligonucleotides.
- Group X, claim 59, drawn to a method of driving lung specific expression of a heterologous polynucleotide using a Jaagsiekte retrovirus genome vector.

2. The inventions listed as Groups I-X do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The asserted special technical feature that links Groups I-X is a Jaagsiekte retrovirus. However, the first named invention, Group I, drawn to a Jaagsiekte retrovirus is anticipated by York *et al* (*Journal of Virology*, September 1991, 65:5061-5067). York teaches the purification of a Jaagsiekte retrovirus containing the gag, env and pol proteins, LTRs and nucleic acid sequences encoding proteins for other function, see page 4930, second column, first and second full paragraphs. The special technical feature is anticipated by York, and therefore the claims lack unity of invention.

3. Inventions I and (II and VI) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to a virus, polynucleotide encoding the virus and an antibody that binds the virus. These products have different structures, functions and modes of operation and effect. They are not disclosed as capable of use together.

Inventions I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product as claimed can be made synthetically.

Inventions I and (IV, VII, IX and X) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to a Jaagsiekte retrovirus and methods that do not require a Jaagsiekte retrovirus.

Inventions I and (V and VIII) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the Jaagsiekte retrovirus can be used in multiple methods, such as inducing an immune response and detecting compounds that bind to Jaagsiekte retrovirus.

Inventions II and (III, IV and X) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product, drawn to a Jaagsiekte genome and

Art Unit: 1648

vector, can be used in materially different methods such as producing a Jaagsiekte retrovirus, treating a subject, and driving lung specific expression of a heterologous polynucleotide.

Inventions II and (V, VII, VIII and IX) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to a Jaagsiekte genome, and methods that do not require the genome and an antibody. The inventions are not disclosed as capable of use together and have different structures (with regard to the antibody).

Inventions III, IV, V, VII, VIII, IX and X are all unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to methods that have different methods steps, reagents, functions and effects. The methods are not disclosed as capable of use together.

Inventions VI and (III, IV, V, VII, VIII, IX and X) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to a methods that do not require the antibody.

Inventions VI and VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP

Art Unit: 1648

§ 806.05(h)). In the instant case the antibody can be used to detect Jaagsiekte retrovirus in a sample.

Because these inventions are distinct for the reasons given above and the literature search required for one group is not co-extensive for any other group, and therefore burdensome, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

4. Papers relating to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 located in Crystal Mall 1. The Fax number for Art Unit 1648 is (703) 308-4426. All Group 1600 Fax machines will be available to receive transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Stacy B. Chen, whose telephone number is (703) 308-2361. The Examiner can normally be reached on Monday through Friday from 7:30 AM-4:00 PM, (EST). If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, James C. Housel, can be reached at (703) 308-4027. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

SBC
Stacy B. Chen
August 18, 2003

James C. Housel
JAMES HOUSEL 8/24/03
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600